Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Radiant Research

Neither a doctor nor a teaching hospital

Research payments

$154,483

92 payments

Through program year 2022, Radiant Research is reported as receiving $154,483 in research payments, across 92 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $2,495 1
2021 Research $417 4
2020 Research $25,954 32
2019 Research $125,617 55

Breakdown

Who paid Research payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $53,677 38 payments
  2. Sandoz Inc. $50,954 2 payments
  3. Allergan Inc. $20,664 37 payments
  4. Novartis Pharmaceuticals Corporation $19,007 3 payments
  5. Pfizer Inc. $4,990 2 payments
  6. Merck Sharp & Dohme Corporation $2,500 3 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $1,533 2 payments
  8. Ucb SA $595 3 payments
  9. Amgen Inc. $375 1 payment
  10. UCB Biosciences Inc. $188 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. Open Label Study of the Solis Dry Powder Inhaler Containing Fluticasone Propionate and Salmeterol Xinafoate When Used in Normal Clinical Practice With Patients $50,954 2 payments
  2. Zoster-049 $19,980 23 payments
  3. A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $19,007 3 payments
  4. Zoster-064 $16,400 10 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $10,989 21 payments
  6. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine $9,360 15 payments
  7. Zoster-056 $8,824 4 payments
  8. Menb Rec 2Nd Gen (V72_92) $8,473 1 payment
  9. A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine V160 in Healthy Adults $2,500 1 payment
  10. A Phase 2B Randomized Doubleblind Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06651600 With A Partially Blinded Extension Period to Evaluate the Efficacy and Safety of Pf06651600 and Pf06700841 in Subjects With Active Nonsegmental Vitiligo $2,495 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record